Cardiovascular Disease

FDA Fast Tracks Empagliflozin to Improve Outcomes Following Heart Attack

September 18, 2020

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

Study: Use of Azithromycin With QT Prolonging Drugs Linked to Cardiac Events

September 18, 2020

A study compared cardiac events associated with azithromycin versus amoxicillin.

Study: Gut Microbiome Data May Be Useful in Screening for Heart Disease

September 10, 2020

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

FDA Approves New Doses of Dulaglutide for the Treatment of Type 2 Diabetes

September 08, 2020

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

Study: No Link Between Antihypertensive Medications and Cancer Risk

September 03, 2020

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.

Dapagliflozin Reduces Risk of Kidney Failure, Death in Chronic Kidney Disease

August 31, 2020

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial

July 31, 2020

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Study Suggests Azithromycin Associated With Heart Death Risk

July 13, 2020

Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

July 03, 2020

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Risk of Death By Heart Failure Increases With Recent Diagnosis of Type 2 Diabetes

July 02, 2020

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.